Risk Predictors of Weight Gain in Chronic Treatment with Valproate in Epileptic Patients
Mohamed Abdelmoneim Abdou Tolba;
Abstract
Background: Valproic acid (VPA) has a broad spectrum of anticonvulsant
activity. However, weight gain is the most common side-effect of VPA
Furthermore, it is well established that weight gain and obesity are
associated with an increase in patients cardiovascular risk and increased
noncompliance or therapy interruption. the present study is focused on
weight gain observed with antiepileptic drugs and its relation to leptin and
insulin hormones
Objective: The aim of this work is to assess potential use of (insulin and
leptin) level as risk predictors of weight gain in long term treatment with
valproate in epileptic patients.
activity. However, weight gain is the most common side-effect of VPA
Furthermore, it is well established that weight gain and obesity are
associated with an increase in patients cardiovascular risk and increased
noncompliance or therapy interruption. the present study is focused on
weight gain observed with antiepileptic drugs and its relation to leptin and
insulin hormones
Objective: The aim of this work is to assess potential use of (insulin and
leptin) level as risk predictors of weight gain in long term treatment with
valproate in epileptic patients.
Other data
| Title | Risk Predictors of Weight Gain in Chronic Treatment with Valproate in Epileptic Patients | Authors | Mohamed Abdelmoneim Abdou Tolba | Issue Date | 2017 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.